ClinicalTrials.gg
TerminatedNCT04527523Updated Jan 13, 2023

Descemet Membrane Endothelial Keratoplasty vs. Descemet's Stripping With Endothelial Keratoplasty vs. Descemet Stripping Only

An observational study in Cystoid Macular Edema and Fuchs Dystrophy, sponsored by Wake Forest University Health Sciences. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-13.

Sponsored by Wake Forest University Health Sciences · Observational

Why this study was terminated
PI does not have the time and support needed to continue the study at this time.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
4
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to evaluate and compare incidence of post-operative cystoid macular edema (CME) after Descemet Membrane Endothelial Keratoplasty (DMEK), Descemet's Stripping Automated endothelial Keratoplasty (DSEK) and Descemet Stripping Only (DSO).

Read the detailed description

Patients that are undergoing any of these procedures will be asked if they are willing to have a baseline pre-operative Optical Coherence Tomography (OCT) scan completed within 4 weeks of surgery. Additional OCT scans will be collected during routine follow up care. It is hypothesized that the rates of CME will be lower with DSO compared to DMEK and DSEK.

02

Conditions studied

  • Cystoid Macular Edema
  • Fuchs Dystrophy

Keywords

  • endothelial transplants
  • endothelial dysfunction
03

In context

Macular Edema

756 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

This study's enrollment of 4 is below the median of 71 across 127 observational studies indexed under Macular Edema.

Browse Macular Edema studies →

Lead sponsor

Wake Forest University Health Sciences is the lead sponsor of 1,351 studies on the registry; 201 are open to participants now.

Of its 332 completed or terminated interventional studies of FDA-regulated products, 251 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with endothelial dysfunction that require treatment, and are being evaluated for Descemet Stripping Only (DSO), Descemet Membrane Endothelial Keratoplasty (DMEK) or Descemet's Stripping Automated Endothelial Keratoplasty (DSEK)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any patient that is undergoing DSO or endothelial corneal transplantation vis DMEK or DSEK

Exclusion criteria

Exclusion Criteria:

  • Patients that do not have an optical coherence tomography measurement pre- operatively
  • Patients that don't have an optical coherence tomography measurement post- operatively
  • Patients with a previous history of uncontrolled macular edema
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
4 participants (actual)
Patient registry
No

Groups and cohorts

  • Endothelial Dysfunction Cohort

    All patients enrolled in the study will receive a baseline Optical Coherence Tomography scan (OCT) within 4 weeks prior to surgery. Two additional OCT scan will be performed 6 weeks and 3 months after surgery.

    Diagnostic Test: Optical Coherence Tomography

Interventions

  • Diagnostic testOptical Coherence Tomography

    OCT is an imaging method that uses light waves to create images of the retina.

    Also known as: OCT

06

What researchers measure

Primary outcomes

  1. Incidence of Post-Op CME

    The frequency (number of Subjects) of post-operative Cystoid Macular Edema will be evaluated for patients receiving DMEK, DSEK or DSO.

    Time frame: 6 weeks post-operative

  2. Incidence of Post-Op CME

    The frequency (number of Subjects) of post-operative Cystoid Macular Edema will be evaluated for patients receiving DMEK, DSEK or DSO.

    Time frame: 3 months post-operative

  3. Severity of Post-Op CME

    The severity of post-operative Cystoid Macular Edema will be evaluated for patients receiving DMEK, DSEK or DSO that experience Cystoid Macular Edema after surgery - measured by net change of Central Foveal Thickness on Optical Coherence Tomography (OCT- is an imaging technique that uses low-coherence light to capture micrometer-resolution, two- and three-dimensional images from within optical scattering media, e.g., biological tissue)

    Time frame: 6 weeks post-operative

  4. Severity of Post-Op CME

    The severity of post-operative Cystoid Macular Edema will be evaluated for patients receiving DMEK, DSEK or DSO that experience Cystoid Macular Edema after surgery - measured by net change of Central Foveal Thickness on Optical Coherence Tomography (OCT- is an imaging technique that uses low-coherence light to capture micrometer-resolution, two- and three-dimensional images from within optical scattering media, e.g., biological tissue)

    Time frame: 3 months post-operative

Secondary outcomes

  1. Graft Detachment

    Frequency (number of Subjects) of post-operative graft detachment will be evaluated in patients that receive a corneal endothelial transplant.

    Time frame: 6 weeks and 3 months post-operative

  2. Re-bubbling Procedure

    The incidence (number of Subjects) of re-bubbling procedures performed post-operatively will be evaluated.

    Time frame: 6 weeks and 3 months post-operative

  3. Infection

    The incidence (number of Subjects) of post-operative infection will be evaluated.

    Time frame: 6 weeks and 3 month post-operative

  4. Final Visual Acuity

    The Snellen Visual Acuity test - This means that the test subject sees the same line of letters at 20 feet that person with normal vision sees at 20 feet. 20/40 vision means that the test subject sees at 20 feet what a person with normal vision sees at 40 feet.

    Time frame: 3 months post-operative

07

Study locations

1 site
  • Wake Forest Health Sciences
    Winston-Salem, North Carolina 27157, United States
08

References and documents

Publications

  • Inoda S, Hayashi T, Takahashi H, Oyakawa I, Yokogawa H, Kobayashi A, Kato N, Kawashima H. Risk Factors for Cystoid Macular Edema After Descemet Membrane Endothelial Keratoplasty. Cornea. 2019 Jul;38(7):820-824. doi: 10.1097/ICO.0000000000001950. PubMed 30973407 ↗
  • Kocaba V, Mouchel R, Fleury J, Marty AS, Janin-Manificat H, Maucort-Boulch D, Burillon C. Incidence of Cystoid Macular Edema After Descemet Membrane Endothelial Keratoplasty. Cornea. 2018 Mar;37(3):277-282. doi: 10.1097/ICO.0000000000001501. PubMed 29298168 ↗
  • Arbelaez JG, Price MO, Price FW Jr. Long-term follow-up and complications of stripping descemet membrane without placement of graft in eyes with Fuchs endothelial dystrophy. Cornea. 2014 Dec;33(12):1295-9. doi: 10.1097/ICO.0000000000000270. PubMed 25299425 ↗
  • Koenig SB. Planned Descemetorhexis Without Endothelial Keratoplasty in Eyes With Fuchs Corneal Endothelial Dystrophy. Cornea. 2015 Sep;34(9):1149-51. doi: 10.1097/ICO.0000000000000531. PubMed 26186374 ↗

Individual participant data

Plan to share: No — IPD will not be shared. Final, overall results will be reported for each outcome.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Aug 2022, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2020
First posted
Aug 26, 2020
StartActual
Nov 21, 2020
Primary completionActual
Aug 24, 2022
CompletionActual
Aug 24, 2022
Last update
Jan 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04527523
Responsible party
Sponsor
First posted
Aug 26, 2020
Start date
Nov 21, 2020
Primary completion
Aug 24, 2022
Completion
Aug 24, 2022
Last update
Jan 13, 2023

Study contacts

Matthew Giegengack
principal investigator · Wake Forest Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion